New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
05:53 EDTQUREuniQure, Medison sign Glybera distribution agreement for Israel
uniQure N.V. and Medison Pharma announced an exclusive distribution agreement under which Medison will market Glybera, uniQure's gene therapy product for the treatment of lipoprotein lipase deficiency, or LPLD, in Israel and the Palestinian Authority. Medison will also be responsible for obtaining regulatory approval for Glybera in both territories. Financial terms of the agreement have not been disclosed. Glybera is approved in the EU as a treatment for LPLD, a potentially life-threatening, orphan metabolic disease that results in patients' inability to process fat in the blood after a meal.
News For QURE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
16:10 EDTQUREPoint72 Asset reports 5.0% passive stake in uniQure
Subscribe for More Information
08:50 EDTQUREuniQure price target lowered to $44 from $50 at Leerink
Leerink lowered its price target to $44 from $50 on uniQure after the company's Q2 report and pipeline update, noting that management said it is reassessing its development options for Glybera in the U.S. after the FDA said another trial would be required to support BLA filing. The firm said the company's key pipeline programs are on track, with initial data from hemophilia B and Sanfilippo B phase 1 trials expected in the second half, and keeps its Outperform rating on uniQure shares.
08:21 EDTQUREuniQure likely to delay Glybera U.S. registration indefinitely, says WallachBeth
Subscribe for More Information
07:25 EDTQUREuniQure weakness creates buying opportunity, says H.C. Wainwright
After uniQure reported a lower than expected per share loss, H.C. Wainwright believes that Hemphilia B is a key value driver for the stock. The firm notes that in a previous Phase 1 trial the same gene cassette being used by the company in an upcoming trial demonstrated continuous expression greater than 5% at the high dose and improved median bleeding episodes by 90%. The firm thinks that the stock should rise sharply if the current trial yields similar results. It keeps a $39 price target and Buy rating on the shares.
August 27, 2015
05:36 EDTQUREuniQure reports Q2 EPS (EUR 87c) vs. (EUR 51c) last year
Subscribe for More Information
August 17, 2015
09:13 EDTQUREuniQure data positive, says Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use